Know Cancer

forgot password

Blinded Cross-over Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia

Phase 1
18 Years
Open (Enrolling)
Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia

Thank you

Trial Information

Blinded Cross-over Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia

To assess the bioequivalence of Vidaza® and Luitpold Azacitidine pharmacokinetics, in terms
of Cmax, AUC0-t and AUC0-∞, following SC administration.

To assess the comparative safety of Vidaza® versus Luitpold Azacitidine during the 2 day
study period.

Inclusion Criteria:

- Signed informed consent obtained prior to initiation of any study-specific

- Patients with one of the following - myelodysplastic syndrome of the following
French-American- British (FAB) subtypes: refractory anemia (RA), RA with ringed
sideroblasts (if accompanied by neutropenia, or thrombocytopenia, or requiring
transfusion), RA with excess of blasts (RAEB), RAEB in transformation (RAEB-T), or
chronic myelomonocytic leukemia (CMMoL); myelofibrosis; chronic myeloid leukemia; or
chronic lymphocytic leukemia who's physician feels should receive azacitidine.

- Male or female patients aged at least 18 years.

- ECOG Performance Status 0-2.

- Life expectancy > or = to 3 months.

- Adequate organ function, including the following: Hepatic - Total bilirubin < or = to
1.5 x the upper limit of normal (ULN), aspartate transaminases (AST) and alanine
transaminases (ALT) < or = to 2 x ULN and Renal - Serum creatinine < or = to 1.5 x

- Female patients of child-bearing potential must have a negative pregnancy test and
must be using at least one form of contraception as approved by the Investigator for
4 weeks prior to the study and 4 months after the last dose of azacitidine.

- Male patients must use a form of barrier contraception approved by the investigator
during the study and for 4 months after the last dose of azacitidine.

Exclusion Criteria:

- Hypersensitivity to azacitidine or mannitol.

- Anticipated need for RBC or platelet transfusion 2 days prior to or up to 2 days
after treatment initiation.

- Chemotherapy (excluding previous azacitidine treatment) or radiotherapy within 4
weeks of randomization (6 weeks for nitrosoureas or mitomycin C).

- Significant electrophysical abnormalities in pre-trial EKG.

- Present history of locally advanced or metastatic malignant disease or leukemia.

- Use of recreational drugs or history of drug addiction, within the prior 6 months.

- Known history of a positive hepatitis screen, including hepatitis B surface antigens
or HCV antibodies.

- Known history of HIV or syphilis.

- History of clinically significant adverse events due to chemotherapy, radiotherapy or
investigational agents.

- Presence of an advanced malignant hepatic tumor.

- Presence of an ongoing or active infection, symptomatic congestive heart failure,
unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia,
uncontrolled thrombotic or hemorrhagic disorder, or any other serious uncontrolled
medical disorders.

- Presence of any significant central nervous system or psychiatric disorder(s) that
would hamper the patients compliance.

- Treatment with any other investigational agent, or participation in another clinical
trial within 28 days prior to study entry.

- Pregnant or breast-feeding patients or any patient with childbearing potential not
using adequate contraception.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Area under the Concentration Time Curve (AUC0-t)

Outcome Description:

Pharmacokinetic Analysis

Outcome Time Frame:

Blood will be drawn pre-dose, and 0.125, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, and 10 hours after dosing on days 1 and 2

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

October 2010

Completion Date:

Related Keywords:

  • Myelodysplastic Syndrome
  • Myelofibrosis
  • Chronic Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Primary Myelofibrosis
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Myelodysplastic Syndromes
  • Preleukemia



Luitpold Pharmaceuticals, Inc.Norristown, Pennsylvania  19403